Semaglutide at 0.25mg: what week 3 actually means for weight loss

What did @yae.gets.fit actually say?

She made three specific claims worth examining. First, that eating protein before her semaglutide injection stopped her nausea cold: "immediately after my injection, I did not get sick." Second, that electrolyte supplementation was responsible for her fatigue recovery, with energy going "through the roof" after taking one electrolyte pack per day for two days. Third, that her returning hunger and cravings in week three meant her body had "gotten used to the medicine" and signaled it was time to dose up. She also mentioned her platform offered to let her skip the 0.5mg dose and jump straight to 1mg, which she wisely declined.

To her credit, she repeatedly acknowledged that individual results vary and framed her approach as personal experimentation rather than universal advice. That's more epistemic humility than most TikTok health content musters.

Does the science back this up?

On the protein-before-injection claim: partially, but the mechanism she implies isn't quite right. On electrolytes curing GLP-1 fatigue: the evidence is thin and her self-experiment had too many confounders to conclude anything. On appetite returning at week three signaling tolerance: that's a real clinical pattern, though the framing oversimplifies it.

Semaglutide-related nausea is well-documented. A 2021 trial published in the New England Journal of Medicine (Wilding et al.) found nausea affected roughly 44% of participants on 2.4mg semaglutide weekly. The mechanism involves GLP-1 receptors in the gut slowing gastric emptying. Having food in the stomach before injection may buffer that effect, though no randomized trial has specifically tested the protein-timing strategy she describes. The clinical guidance from most prescribers does include eating before injection as a practical nausea-reduction strategy, so she's not wrong in spirit.

On electrolytes: GLP-1 medications can cause fluid and electrolyte losses, particularly if nausea leads to reduced intake. Sodium and potassium deficits can absolutely cause fatigue. But her experiment, two days on, one day off, with a forgotten dose on day three yet still feeling fine, doesn't isolate the electrolyte variable from the natural GLP-1 adaptation curve that occurs over weeks.

What did they get wrong (or right)?

She got the appetite-suppression-returning pattern mostly right, but attributed it to the wrong cause. Saying her body "gotten used to the medicine" implies pharmacological tolerance, which isn't really how semaglutide works. GLP-1 receptor downregulation isn't the primary driver of appetite returning at low doses. More likely, 0.25mg is simply a subtherapeutic starting dose by design, not a therapeutic target. The STEP trials used doses up to 2.4mg weekly. At 0.25mg, meaningful appetite suppression was never guaranteed.

The protein-timing strategy she describes, roughly 39 grams split before injection, is creative and anecdotally reported across GLP-1 communities. It's not evidence-based in a clinical trial sense, but it's also not harmful. Protein does slow gastric emptying independently, which may modulate how the drug's GI effects hit. Calling this a discovery, though, is a stretch. It's a reasonable behavioral workaround, not a validated protocol.

She was right to decline jumping from 0.25mg to 1mg. Skipping titration steps is associated with significantly higher rates of GI adverse events, per prescribing guidelines across branded semaglutide products.

What should you actually know?

A few things here matter clinically. Nausea management on GLP-1 medications is legitimately understudied in terms of behavioral interventions. Most guidance is expert opinion, not RCT data. Eating before injection is commonly recommended by prescribers and appears to help many patients, but the specific macronutrient composition of that pre-injection meal hasn't been tested in controlled settings.

Electrolyte depletion is a real concern on GLP-1 therapy, especially in early weeks when nausea may reduce overall food and fluid intake. A 2023 review in Obesity Reviews (Rubino et al.) noted that GI side effects are the leading cause of early discontinuation. Proactively managing hydration and electrolytes is clinically reasonable, though the specific dosing schedule she invented for herself is not a medical recommendation.

The dose titration schedule she described, four weeks at each level before increasing, reflects standard clinical practice for minimizing side effects. Her instinct to stick with it rather than rush to 1mg reflects good judgment. Anyone on semaglutide should be working with a licensed prescriber, not calibrating doses based on TikTok community feedback or hunger levels alone.